Immuno-PET of cancer: a revival of antibody imaging.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed.

1. LAMP1 as a Target for PET Imaging in Adenocarcinoma Xenograft Models.Pharmaceuticals (Basel, Switzerland) · 2025
   Article
2. Cancers · 2023
   Article
3. Pretargeted imaging beyond the blood-brain barrier.RSC medicinal chemistry · 2023
   Article
4. Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
5. Improved Quantification ofDiagnostics (Basel, Switzerland) · 2019
   Article
6. Selection Criteria for Determination of Optimal Reconstruction Method for Cu-64 Trastuzumab Dosimetry on Siemens Inveon PET Scanner.Journal of clinical medicine · 2019
   Article
7. Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.Frontiers in medicine · 2019
   Review
8. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.PET clinics · 2018
   Review
9. Multifunctional Desferrichrome Analogues as VersatileMolecular pharmaceutics · 2017
   Article
10. In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme.Molecular pharmaceutics · 2017
    Article
11. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.PET clinics · 2017
    Review
12. Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.Theranostics · 2017
    Review
13. Immuno-PET for Clinical Theranostic Approaches.International journal of molecular sciences · 2016
    Review
14. ImmunoPET to help stratify patients for targeted therapies and to improve drug development.European journal of nuclear medicine and molecular imaging · 2016
    Article
15. Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.Nuclear medicine and molecular imaging · 2016
    Review
16. Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.Physics in medicine and biology · 2015
    Review
17. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.European journal of nuclear medicine and molecular imaging · 2015
    Article
18. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.Nature methods · 2015
    Article
19. Tumor immunotargeting using innovative radionuclides.International journal of molecular sciences · 2015
    Review
20. Challenges in nuclear medicine: innovative theranostic tools for personalized medicine.Frontiers in medicine · 2014
    Article

Corrections and comments

• Comment on
  (124)I-huA33 antibody PET of colorectal cancer.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as